Objectives/Hypothesis: To investigate the role of Smad3 as a regulator of transforming growth factor (TGF)-b1-mediated cell activities associated with fibrosis in normal human vocal fold fibroblasts. We also sought to confirm the temporal stability of Smad3 knockdown via small inhibitor ribonucleic acid (siRNA). Vocal fold fibroblasts were employed to determine the effects of Smad3 knockdown on TGF-b1-mediated migration and contraction, as well as regulation of connective tissue growth factor (CTGF). We hypothesized that Smad3 is an ideal candidate for therapeutic manipulation in vivo based on its role in fibrosis.
INTRODUCTION
The biophysical demands placed upon the vocal fold mucosa are profound and place the tissue at increased risk for long-term architectural changes associated with the inherent wound-healing response. This response is complex, involving multiple cell types as well as extracellular matrix. Recently, several laboratories provided substantive data regarding the processes underlying vocal fold wound healing, with the ultimate goal of improved therapies to both avoid and/or treat vocal fold fibrosis. Given that the vocal fold mucosa is subjected to trauma associated with phonation, with minimal changes to the vocal fold structure at baseline, a threshold likely exists with regard to the type and/or duration of injury that leads to the fibrotic tissue phenotype. Although this threshold has not been characterized and is likely variable across individuals, our laboratory and others have focused on key biochemical triggers responsible for this amplified wound-healing response, yielding tissue fibrosis and ultimately aberrant phonatory physiology.
In this regard, transforming growth factor (TGF)-b1 has been identified as one key mediator of fibrosis and is ubiquitous in both uninjured and injured tissue. Transforming growth factor-b1 regulates both wound healing in general, and more specifically the development of fibrosis through its interactions with mesenchymal cells. Transforming growth factor-b1 affects numerous fibroblast activities, including proliferation; adhesion; migration; apoptosis; and the production, degradation, and accumulation of extracellular matrix (ECM) proteins. Relevant to fibrosis, TGF-b1 stimulates fibroblasts to produce large amounts of ECM, including collagen and proteoglycans; it is implicated in excessive ECM deposition across numerous pathological fibrotic conditions, including in the liver, lung, kidney, skin, heart, and arterial walls. [1] [2] [3] [4] [5] [6] [7] [8] Several laboratories, including ours, have implicated TGF-b1 as a mediator of vocal fold scar. 9, 10 transcription (Fig. 1) . Activated Smads have been implicated in a variety of fibrotic processes, suggesting that Smad activation plays a central role in both collagen production and accumulation in these diseases. Preliminary investigation by our laboratory confirmed upregulation of Smad3 messenger (m)RNA following acute vocal fold injury. 11 Globally, we hypothesize that Smad3 is a master regulator of fibrosis, and manipulation of Smad3 via RNA-based therapies holds significant clinical promise. Specifically, the loss of Smad3 has been shown to interfere with TGF-b1-mediated induction of genes for collagens and tissue inhibitors of metalloproteinases, and Smad3-null mice are resistant to radiation-induced cutaneous fibrosis, bleomycin-induced pulmonary fibrosis, carbon tetrachloride-induced hepatic fibrosis, glomerular fibrosis, and many other fibrotic conditions. 12 Our laboratory recently performed direct injections of small inhibitor ribonucleic acid (siRNA) targeting Smad3 siRNA into rabbit vocal fold mucosa, and therapeutic RNA interference is increasing in popularity across tissue systems and disease processes. 13 In the current study, we sought to further describe the role of Smad3 as a mediator of the fibrotic phenotype in our normal human vocal fold fibroblast cell line in vitro based on our global hypothesis that Smad3 is a physiologically relevant target for antifibrotic therapies in the vocal folds.
MATERIALS AND METHODS

Cell Model
All experiments employed the immortalized human vocal fold fibroblast cell line created in our laboratory, referred to as HVOX. 10 This line has been shown to stable through multiple population doublings; the current experiments employed cells in passages 20 to 30. All cells were maintained in Dulbecco's Modified Eagle Medium (DMEM), supplemented with 10% fetal bovine serum (FBS) and antibiotic/antimycotic. Recombinant human TGF-b1 (Life Technologies, Grand Island, NY) was employed in all experiments.
Transfection
As described previously by our laboratory, 11 HVOX were grown to 60% to 80% confluence and treated with serum-free media overnight prior to experimentation. Cells were then washed twice with phosphate-buffered saline (PBS) and treated with Opti-MEM media with 10% fetal bovine serum (no antibiotic/antimycotic) and Lipofectamine (Thermo Fisher Scientific, Waltham, MA) 2000 (1mg/mL) and siRNA for either Smad3 or nonsense sequence. Cells were treated with this complex and gently agitated for 6 hours. The transfection media was then removed and replaced with fresh media containing TGF-b1, when appropriate.
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis
At the experimental endpoint, cells were washed twice with cold PBS, and a cell scraper was employed to free the cells from the plates. The cells were then resuspended in a 1.5-ml tube and centrifuged at 3000 rpm for 3 minutes at 48C. The supernatant was aspirated, and the pellet was then lysed via Mammalian Protein Extraction Reagent (Thermo Scientific, Waltham, MA), supplemented with Halt Protease inhibitor cocktail (Thermo Scientific, Waltham, MA), 0.5M EDTA Solution 100x (Thermo Scientific), and Calyculin A (Cell Signaling, Danvers, MA) on ice for 10 minutes. The tubes were then centrifuged at 14,000 rpm for 10 minutes at 48C and transferred to fresh tube. Total protein content was quantified with Pierce 660 nm Protein Assay kit (Thermo Scientific) and a Synergy H 1 Hybrid Reader (BioTek, Winooski, VT), employing the manufacturer standard protocol. Sodium dodecyl sulfate polyacrylamide gel electrophoresis was then run via standard protocol and then transferred overnight at 48C. The membranes were then blocked in nonfat milk and incubated with the primary antibody (connective tissue growth factor [CTGF], Smad7, or glyceraldehyde 3-phosphate dehydrogenase [GAPDH]; Abcam, Cambridge, U.K.; 1:1000) overnight at 48C. The membranes were then treated with the secondary antibody Anti-rabbit immunoglobulin G (Cell Signaling, Danvers, MA) for 1 hour at room temperature and then developed using chemiluminescent film.
Collagen Contraction
PureCol (Advanced BioMatrix, San Diego, CA) collagen gels were made using the standard protocols.
14, 15 The pH was adjusted to 7.2 to 7.5, and then the gel was dispensed inside 0.5-inch Teflon rings (Cannon Gasket Inc., Fontana, CA) and incubated for 30 minutes at 378C to allow gelation. Human vocal fold fibroblast cells were seeded onto the gels at a concentration of 3 3 10 4 cells in 200mL (1.5 3 10 5 /mL) and incubated for 2 hours. The gels were then treated with 2mL of media supplemented with 5% FBS 6 TGF-b (20ng/mL) (Life Technologies, Grand Island, NY). The Teflon washers were then carefully removed, and the gels were freed from the underlying surface of the cell culture plate. Gels were imaged immediately upon treatment and then again at 6 hours with a digital 8-megapixel camera (Apple, Inc. Cupertino, CA). Changes in collagen gel area were analyzed using ImageJ (National Institutes of Health). Cell Migration/Scratch Assay Cell migratory rate was quantified via standardized techniques previously described by our laboratory. 10, 16 The HVOX were grown in T25 culture dishes until 100% confluent. The cells were then transfected using standard transfection protocols (see above). Using a small pipette tip, a gentle scratch was made laterally across the T25 from one end to the other. Transverse lines with a marker were drawn on the bottom of the T25 to serve as a reference. Cells were supplemented with 2-ml DMEM with 5% FBS 1/2TGF-b1. The scratch was photographed using a Nikon Eclipse TS100 microscope (Nikon, Inc. Melville, NY) with an attached C mount Morrell HDMI-02 camera (Morrell Instrument Company, Melville, NY). The cells were imaged at 43 magnification at 0 and 8 hours. The denuded area was then quantified in pixels using ImageJ (National Institutes of Health). The migratory rate was then calculated as: initial area-final area 5 D area/8 hours.
Quantitative Polymerase Chain Reaction
Ribonucleic acid was extracted from HVOX cells using the RNeasy Mini Kit (Qiagen, Venlo, Netherlands) under standard protocol and then reverse transcribed using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Quantitative polymerase chain reaction (PCR) was run by using the TaqMan Gene Expression kit (Life Technologies, Waltham, MA) and the StepOnePlus Real-Time PCR System (Applied Biosystems). Primer probes for Samd3 (Hs00969210_m1), Smad7 (Hs00998193_m1), and GAPDH (Hs02758991_g1) as an exogenous control were purchased from Life Technologies (Norwalk, CT).
Statistical Analyses
All experiments were performed in triplicate, at least. Information regarding the number of independent experiments is provided on each figure. For all analyses, the dependent variable of interest was subjected to a one way analysis of variance at P 5 0.05. If the main effect was significant, post hoc comparisons were performed via the Tukey method (P 5 0.05). All analyses were performed using SPSS 22 (IBM Corp., Armonk, NY).
RESULTS
Smad3 Knockdown Is Efficient and Prolonged With Small Inhibitor RNA
Treatment of HVOX cells with transfection media for 6 hours yielded consistent and efficient Smad3 knockdown, as previously reported by our laboratory. 11 The main effect for knockdown was significant (P < 0.001). At 24 hours, knockdown was 80%, as previously described by our laboratory. This level of knockdown was maintained through 72 hours posttransfection, as confirmed via post-hoc pairwise comparisons (Fig. 2) . Nonsense siRNA had no statistically significant effect on Smad3 mRNA expression in our cells.
Smad3 Knockdown Blunted Transforming Growth Factor-b-Mediated Collagen Gel Contraction
The main effect for contraction was significant (P < 0.000) (Fig. 3A) . Smad3 knockdown reduced collagen gel contraction at baseline by 65%; this reduction was statistically significant (P < 0.001). In contrast, TGF-b1 (10 ng/mL) stimulated a statistically significant increase in the contractile phenotype (P 5 0.024). This TGF-bmediated response was reduced to levels similar to Smad3 knockdown without TGF-b1 treatment; the reduction was significant when compared to both control (P < 0.001) and TGF-b1 treatment (P < 0.001). Nonsense siRNA had no effect on the contractile phenotype in our cells. Representative images are shown in Figure 3B .
Smad3 Knockdown Did Not Affect Transforming Growth Factor-b1-Mediated Cell Migration
As shown in Figure 4 , TGF-b1 at concentrations of 10 and 20 ng/mL stimulated cell migration. The main effect for migration was significant (P < 0.001). In the Smad3 knockdown condition, however, TGF-b1 at both concentrations stimulated a qualitative increase in migratory rate. This increase did not achieve statistical significance (P 5 0.347 at 10 ng/mL and P 5 0.319 at 20 ng/mL).
Smad3 Knockdown Limits Transforming Growth Factor-b-Mediated Connective Tissue Growth Factor Translation
Although CTGF protein was observed at baseline (e.g., control), marked upregulation of CTGF was observed in response to TGF-b1 (10 ng/mL) at both 12 and 24 hours. As shown in Figure 5 , CTGF protein levels were below control levels in response to Smad3 knockdown. Nonsense siRNA had no effect on CTGF protein levels.
Smad3 Knockdown Altered Smad7 Translation in Response to Transforming Growth Factor-b1
As noted previously by our laboratory, 10 TGF-b1 (10ng/mL) stimulated increased in Smad7 mRNA expression and translation at both 6 and 24 hours; the main effect was significant (P < 0.001 and P 5 0.002, respectively). Neither Smad3 nor nonsense siRNA reduced Smad7 transcription at either time point (Fig. 6A ) (P 5 0.939 and P 5 0.995, respectively). Qualitatively, however, a slight decrease in Smad7 protein was observed at both time points (Fig. 6B) .
DISCUSSION
Vocal fold scar continues to pose a profound clinical quandary because it can affect both glottic closure as well as overall mucosal pliability. Treatments to date have largely been directed at the former. The identification of key biochemical triggers responsible for the fibrotic vocal fold tissue phenotype is critical to the development of novel, physiologically based therapeutics for this challenging patient population to direct tissue healing toward a more regenerative, less fibrotic outcome. Data across tissue systems, including the vocal folds, implicate TGFb1-and more specifically, Smad3-as a master regulator Fig. 4. (A) The effects of TGF-b1 on cell migration (mean 1/2SEM). TGF-b1 had a dose-dependent effect on cell migration at both 10 and 20 ng/mL (P 5 0.031 and P 5 0.002, respectively). Migratory rate increased in response to TGF-b1 in the context of Smad3 knockdown. This response, however, was not statistically significant when compared to control/untreated cells (P 5 0.347 at 10 ng/mL and P 5 0.319 at 20 ng/mL). (B) Representative images (nonsense small inhibitor RNA not shown). SEM 5 standard error of the mean; TGF-b1 5 transforming growth factor-b1; N/S = nonsense. [Color figure can be viewed in the online issue, which is available at www.laryngoscope.com.] Fig. 5 . Representative sodium dodecyl sulfate polyacrylamide gel electrophoresis gels probed for CTGF at 12 and 24 hours. TGF-b1 stimulated CTGF expression, and this response was attenuated by Smad3 knockdown at both time points. CTGF 5 connective tissue growth factor; TGF-b1 5 transforming growth factor-b1; N/S = nonsense. of fibrosis. Our laboratory hypothesizes that therapeutic targeting of Smad3 will yield substantive change in the response to injury in the vocal folds.
In the current study, we sought to build upon on preliminary work describing the in vivo and in vitro effects of knocking down Smad3 gene expression via siRNA. Specifically, we sought to confirm temporal stability of Smad3 knockdown in our immortalized, normal human vocal fold fibroblast cell line. Transfection of these cells with siRNA for Smad3 lead to prolonged knockdown for 72 hours. Ribonucleic acid interference, or RNAi with siRNA, is a method for gene silencing that triggers sequence-specific mRNA degradation. These techniques have become a useful tool to knock down endogenous expression levels of specific genes and to then observe effects of this altered expression on individual cells. 17 Modification of gene expression in the local tissue environment, such as the vocal folds, is critical for eventually optimizing and individualizing cell therapies for patients. Efficient and temporally prolonged knockdown in our cell line are encouraging preliminary steps in this regard.
Transforming growth factor-b1 exerts its profibrotic effects through both direct and indirect mechanisms via induction of secondary profibrotic mediators, including CTGF, which has been implicated as a downstream mediator of TGF-b1-induced fibroplasia due to its effects on fibroblasts. 18 Interestingly, the precise role of CTGF in the vocal fold fibrosis has not been elucidated to date. However, CTGF mRNA expression in vocal fold fibroblasts appears responsive to injury-associated prolonged exposure to laryngopharyngeal reflux. 19 Regardless, CTGF induction via TGF-b1 in our cell line was Smad3-dependent, as has been described in other cell types, including human renal proximal tubule epithelial cells, 20 which is suggestive that Smad3 mediates both the direct and indirect mechanisms underlying TGF-b1-mediated fibrosis.
Several in vitro cell activities are thought to be related to fibrosis in vivo beyond extracellular matrix metabolism, including contraction and cell migration. With regard to these fundamental cell activities, our data suggest that Smad3 altered the inherent cell response to exogenous TGF-b1. With regard to contraction, the contractile properties of vocal fold fibroblasts have not been described previously. Several studies, however, employed contraction as a dependent variable related to fibrosis in the subglottis. 14, 15, 21, 22 Contraction by fibroblasts is largely dictated by actin cytoskeletal forces generated inside the cells. As wound healing progresses, fibroblast differentiation into myofibroblasts increases these contractile forces due to up-regulation of a-smooth muscle actin. 23 Fibrosis is characterized by prolonged myofibroblast presence and activity in the wound bed. Therefore, increased gel contraction in vitro is likely indicative of a fibrotic tissue phenotype in vivo. In our cell line, Smad3 knockdown limited TGF-b1-mediated collagen gel contraction. The effect on cell migration is a bit more nuanced and subtle. Transforming growth factor-b1 increased cell migration even in the context of Smad3 knockdown; however, this increase did not achieve statistical significance. The role of Smad3 in cell migration has not been previously reported and warrants further investigation.
The response to injury is complex, and the TGF-b signaling pathway involves an inherent antifibrotic feedback loop. As noted previously, Smad2 and Smad3 are receptor-activated or pathway-restricted (R-Smads) proteins directly activated by TGF-b. TGF-b1 binding to the receptor phosphorylates the R-Smads, leading to heterodimerization with Smad4, and this complex translocates to the nucleus to regulate transcription. In addition, the system includes homologs to R-Smads that function as competitive inhibitors of Smad activation, namely Smad7. Constitutive Smad2, Smad3, and Smad7 mRNA expression in vocal fold fibroblasts was described by our laboratory previously. 10 In the current study, we sought to determine the effects of altered Smad3 signaling on Smad7 mRNA and protein expression. In our cell line, induction of Smad7 does not appear to be Smad3-dependent. This finding is encouraging because it appears that vocal fold fibroblasts maintain this inherent antifibrotic mechanism in the context of exogenous regulation of profibrotic gene expression. In the case of scar or keloids in the skin, a relative imbalance skewed toward profibrotic mediators at the expense of antifibrotic mediators dictates directs fibroplastic fibroblast activity. 24 As such, our data are encouraging because Smad3 knockdown does not appear to contribute to this imbalance. In vitro investigation is not without limitation, and caution should be taken with data of this sort. Beyond the inherent, contrived nature of in vitro experimentation, our cell line was acquired from a healthy woman with no known vocal fold pathology. One may hypothesize that a normal cell line may, in fact, respond quite differently to exogenous mediators of wound healing than a cell line obtained from actual fibrotic tissue. With these limitations in mind, we remain optimistic regarding the role of Smad3 in mediating tissue fibrosis. Data from the current study provide further foundation for continued investigation to eventually develop physiologically based therapies for millions of patients.
CONCLUSION
Smad3 consistently regulates in vitro TGF-b1-mediated cellular activities in our normal vocal fold fibroblast cell line that are thought to be consistent with fibroplasia in vivo. Knockdown of Smad3 via siRNA is consistent and temporally prolonged. Cumulatively, these data continue to suggest that RNA-based therapeutics targeting Smad3 may hold significant clinical promise.
